Identification of PfPMIX protein substrates in P. falciparum. WM4 and WM382 are inhibitors of P. falciparum growth because of potent inhibition of the proteolytic function of the aspartic proteases PMIX and PMX3. WM4 is a selective inhibitor of PMX whilst WM382 blocks both PMIX and PMX function in P. falciparum. Protein substrates have been identified that are proteolytically processed by PfPMX, however, only a few have been identified that are specifically cleaved by PMIX1, 2, 3. To discover potential protein substrates of PfPMIX in P. falciparum asexual stage proteins known to be processed that have potential PMIX and X substrate recognition sequences were investigated. This identified the P. falciparum rhoptry neck protein 6 (PfRON6)11, rhoptry-associated membrane antigen (PfRAMA)12, 13 and rhoptry-associated leucine zipper-like protein (PfRALP1)14 as potential PMIX substrates.
To test if PMIX was involved in the proteolytic processing of PfRON6, PfRAMA and PfRALP1, P. falciparum parasites that expressed haemagglutinin (HA) epitope-tagged forms of each protein were generated. The PMX-specific inhibitor WM4 and the PMIX/PMX dual inhibitor WM382 were used to determine if they inhibited processing of PfRON6, PfRAMA or PfRALP1 (Fig. 1). Processing of SERA5, which is mediated by SUB1, a protease activated by PMX, was used as a control (Fig. 1A)1, 2, 3. As expected, both WM4 and WM382 inhibit processing of SERA5 3. In contrast, processing of PfRON6 from p114 to p106 was inhibited by WM382 but not WM4 (Fig. 1B) suggesting PMIX and not PMX was involved. Similarly, processing of PfRAMA (Fig. 1C) and PfRALP1 (Fig. 1D) were more efficiently inhibited by WM382 compared to that observed for WM4, again indicating that PMIX was required. These results are consistent with proteolytic processing of PfRON6, PfRAMA and PfRALP1 being mediated by PMIX or that this aspartic protease activates other proteases required for these cleavage events.
Substrate specificity of PMIX and PMX. To understand the substrate specificity of these aspartic proteases in Plasmodium spp. active recombinant P. falciparum PMX (PfPMX)3, P. falciparum PMIX (PfPMIX) and P. vivax PMX (PvPMX) were expressed and purified to enable detailed kinetic and structural analyses (Fig. S1). PfPMX expression and purification of the active mature enzyme domain has been described previously and this protease has been shown to be autocatalytic3. The recombinant expression products expressing the full-length zymogen form of PvPMX and PfPMIX were the active mature enzyme domains consistent with autocatalytic activity (Fig. S1)3.
To show purified PfPMIX, PfPMX and PvPMX proteases were enzymatically active and to explore their substrate specificity, a fluorogenic assay15 was employed to investigate their ability to cleave peptide substrates designed from known PMX and PMIX processed sites1, 2, 3, as well as putative cleavage sites we identified for PfRON6, PfRAMA and PfRALP1 (Fig. 1E-G). PfPMX was able to cleave the peptide substrates to differing extents, as has been shown previously3, and it was also able to cleave putative PMIX recognition peptides identified in PfRON6, PfRAMA and to some extent PfRALP1 (Fig. 1E). Similarly, PvPMX showed a near identical cleavage pattern as PfPMX in cleaving this broad range of peptide substrates indicating this recombinant protein was active and that these proteases had very similar substrate specificities (Fig. 1F).
In contrast, PfPMIX showed efficient cleavage of peptide substrates PfRh2N, PfRON3, PvRON3 and PfRAMA only and was not able to cleave those corresponding to other known PMIX or PMX processed proteins (Fig. 1G). This suggested PfPMIX either has a more restricted substrate specificity compared to PfPMX and PvPMX, possibly due to subtle differences in the structure of its substrate binding cleft or was less efficient in its ability to cleave peptide substrates compared to full-length proteins, which may have additional localised structure to assist binding to the enzyme. PfRON3 in P. falciparum parasites is processed by PfPMIX3 and the ability of this enzyme to cleave the PfRAMA and PvRAMA peptide sequence corresponding to the proposed processing site was consistent with these proteins being direct protein substrates of PMIX in the parasite (Fig. 1G). Cleavage of the PfPMX peptide substrate PfRh2N by PfPMIX suggests that this protease can process PMX protein substrates when they can be accessed by the active site. PfPMIX was not able to efficiently cleave the PfRON6 or PfRALP1 peptides or other peptides from known PMIX protein substrates such as PfASP and PfRAP1 (Fig. 1G)1, 2, 3. This suggests that either PfRON6 and PfRALP1 are processed by another protease that is activated by PMIX processing1, 2, 3, or it was much less efficient at cleaving peptide substrates compared to full-length protein substrates.
To determine if PfPMIX could process full-length protein substrates, we expressed and purified P. falciparum Apical Sushi Protein (PfASP)16 and PfRh5-interacting protein (PfRipr)17 as recombinant proteins (Fig. 1H, I, J). PfASP is 83 kDa but migrates aberrantly in SDS/PAGE, likely because of the number of charged amino acids, and it has been shown to be a substrate of the protease PfPMIX in P. falciparum (Fig. 1I)1, 2, 3. PfASP is processed by PfPMIX at a known site resulting in a C-terminal p43 proteolytic fragment (43 kDa) (Fig. 1H)3 with the fate of the N-terminal p40 fragment remaining unknown3. Although PfASP is a substrate for PfPMIX in P. falciparum1, 2, 3, a peptide containing the cleavage motif that produces the p43 and p40 fragments was not processed by recombinant PfPMIX and inefficiently by PfPMX and PvPMX (Fig. 1E-G). Digestion of recombinant full-length PfASP using recombinant PfPMIX resulted in the production of the p43 C-terminal polypeptide fragment, as seen in the parasite3, but unexpectedly the p40 fragment was not seen, instead a smaller fragment (p32) was observed in the SDS-PAGE band profile of the digest indicating the existence of a possible second cleavage site (Fig. 1I). Inspection of the sequence confirmed a second cleavage site that would result in a 32 kDa fragment (p32) and a much smaller 8 kDa fragment (p8). Incubation of PvPMX with full length PfASP resulted in the formation of the p43 and p40 fragments (Fig. 1J). However, the digestion involved cleavage at a single motif and did not progress further to produce the p32 fragment, as seen in the PfPMIX digestion of PfASP (Fig. 1I). This indicates the production of the p32 fragment in PfASP was the result of a two-step cleavage event mediated by PfPMIX, which occurs via the p40 intermediary fragment in PfASP. Although PvPMX can promiscuously cleave the first motif it did not cleave the second motif due to differences in substrate specificity for the substrate which can be imposed by substrate structure or a subtle difference in the structure of the enzyme binding cleft.
Following removal of its signal sequence, PfRipr is predicted to be a 123 kDa protein which is a substrate of PfPMX in P. falciparum3. PfRipr is processed by PfPMX at a single site to convert the 123 kDa protein into two polypeptides (p64 and 59 kDa) (Fig. 1H)3. Recombinant PfPMIX was unable to process the PfRipr cleavage motif in either a peptide (Fig. 1G) or in the full-length protein (p123) as there was no observable difference between the protein band profiles in the control lanes with the PfRipr only control and the PfRipr/PfPMIX digest (Fig. 1J). Recombinant PfPMX and PvPMX were not effective at processing a peptide substrate with the cleavage motif for PfRipr (Fig. 1E, F). However, recombinant PvPMX was able to cleave full-length PfRipr protein (p123) into two polypeptides corresponding to p64 and p59 in P. falciparum parasites3 (Fig. 1J). These results indicate that the PfRipr cleavage motif interaction with PvPMX requires additional structural interactions provided at the enzyme/protein substrate interface to enable efficient processing. These digests also validate PfRipr as a substrate of PMX but not PMIX and importantly reveal evidence that different and unique specificities can exist between these two enzymes due to protein substrate structure.
PfPMIX has subtle differences in substrate specificity for cleavage of the PfRON3 peptide. To further understand the substrate specificity of PfPMIX, PfPMX and PvPMX the ability of each protease to cleave the PfRON3 peptide sequence was tested and compared with peptides in which specific amino acids were mutated to alanine (Fig. 2A). Firstly, the cleavage site within the PfRON3 (and PfRh2N) peptides following digestion with PMIX and PvPMX were identified by mass spectrometric analysis (Fig. S2). The phenylalanine of each peptide was shown to be the P1 position with cleavage by PvPMX and PfPMIX between it and the Leucine/Isoleucine residue (P1’). This was the same cleavage position as was determined for PfPMX3. Both PfPMX and PvPMX gave very similar patterns of cleavage for the wild type and mutant RON3 peptides consistent with them having very similar substrate specificities (Fig. 2A). Surprisingly, the P1 phenylalanine was not essential as both PfPMX and PvPMX showed relatively efficient cleavage (RON3 m3 mutant). In contrast, the P1’ and P3’ isoleucine and the P4’ aspartate residues were important as the ability of these proteases to process the corresponding mutant peptides was reduced (RON3 m4, m6 and m7b mutants). This data was consistent with both PfPMX and PvPMX having essentially identical substrate specificities (Fig. 1E and F).
In contrast, PfPMIX showed distinct differences with respect to its ability to cleave the RON3 mutant peptides compared to PfPMX and PvPMX suggesting subtle variance in substrate specificity (Fig. 2A). Similar to the results observed with PfPMX and PvPMX, the P1 phenylalanine residue was not essential as PfPMIX was still able to cleave the peptide, albeit weakly (m3 mutant). However, the P1’ isoleucine, P2’ glutamine, P3’ isoleucine and P4’ aspartate appear to be essential for efficient cleavage by PfPMIX (RON3 m4 - m7 mutants). This suggests that there is variation in substrate specificity for PfPMIX compared to the PMX proteases likely due to amino acid differences in the active site of the proteases (Fig. S3). Despite the contrasting ability to cleave the mutant RON3 peptides a sequence logo representation of PfPMIX cleavage sequences (Fig. 2B), compared to that for PfPMX3, showed close similarity across the core substrate recognition sequence.
WM4 is a selective inhibitor of PMX and WM382 is a dual inhibitor of both PMIX and PMX. Previously, we have shown that WM4 is a PMX specific inhibitor whilst WM382 is a dual inhibitor of both PMIX and PMX protease function in P. falciparum3. Whilst WM4 and WM382 are potent inhibitors of P. falciparum growth, with an EC50 of 7.4 nM and 0.39 nM respectively (Fig. 2C), the molecular basis for the differential inhibition of these compounds with respect to their inhibition of PMIX and PMX function is not known. To gain an understanding of the molecular interactions of WM4 and WM382 with PfPMX, PvPMX and PfPMIX we analysed the kinetics of inhibition (Ki) for peptide cleavage. PvPMX and PfPMIX efficiently cleaved the PfRON3 and PfRh2N peptides respectively at optima pH 5 to pH 5.5 (Fig. S4). WM4 has a similar Ki for PfPMX (0.446 nM) and PvPMX (0.408 nM) with PfPMIX having a significantly higher Ki (263 nM) with a >590-fold increase in the inhibitory effect against PfPMX and PvPMX over PfPMIX (Fig. 2C). This was consistent with WM4 specifically inhibiting PMX proteolysis but not cleavage of PMIX protein substrates in P. falciparum3. WM382 also had a similar Ki for inhibition of PfPMX (0.014 nM) and PvPMX (0.007 nM) as did WM4 consistent with them both being potent inhibitors of PMX enzyme activity. However, WM382 was also a potent inhibitor of PfPMIX (Ki = 0.4 nM), a 29-fold increase in the inhibitory effect against PfPMX over PfPMIX.
The equilibrium dissociation constant (KD) for the affinity of WM4 binding to PvPMX (0.48 ± 0.08 nM) and PfPMX (0.39 ± 0.07 nM) was very similar as were the kon (PfPMX 6.3 ±2.3 x 106 M−1s−1, PvPMX 7.6 ± 5.4 x 106 M−1s−1) and koff (PfPMX 2.4 ± 0.8 x 10−3 s−1, PvPMX 3.4 ± 2 x 10−3 s−1) rates (Fig. 2D and F, Table S1). This was consistent with the conservation of the active site of these proteases (Fig. S2) and showed that this compound bound strongly to these enzymes. In contrast, the KD of WM4 for PfPMIX (77 ± 13 nM) showed a 160-fold lower affinity of binding with the kon (6.0 ± 3.1 x 105 M−1 s−1) and koff (4.7 ± 3.0 x 10−2 s−1) rates also significantly lower (Fig. 2H, Table S1). These results are consistent with WM4 being a specific inhibitor of PfPMX but not PMIX protease function in P. falciparum parasites3. WM382 bound the three enzymes with very high affinity, with a KD of <0.1 nM. The dissociation curves were flat for all proteases and it was not possible to determine koff rates and therefore a KD as the response did not decrease below 5% during the 25 min dissociation phase (Fig. 2E, G and I). This data was consistent with the potent enzyme inhibition observed and showed there were no measurable differences in the KD for WM382 between PfPMX, PvPMX or PfPMIX. These results also suggest that the high potency of WM382 for inhibition of PfPMX, PvPMX and PfPMIX was driven to a great extent by the very slow off rates for binding of the compound.
Structure of P. falciparum PMX. To understand the structural basis for the specificity for WM4 inhibition of PMX compared to the dual specificity of WM382 to inhibit both PMIX and PMX crystal screens were performed with the apo enzymes as well as in complex with WM4 and WM382 for PfPMX, PvPMX and PfPMIX. Diffracting crystals were obtained for the PfPMX apo protease as well as the protein/drug complexes PfPMX/WM382, PvPMX/WM382 and PvPMX/WM4.
A crystal structure of the apo protease PfPMX was obtained at a resolution of 1.85 Å (Fig. 3A and B). PfPMX has a canonical aspartyl protease fold with a crescent shape and a predominantly b-sheet core (Fig. 3B)18, 19. The N- and C- terminal subdomains are anchored via a six stranded interdomain b-sheet. The uppermost b-strand (PfPMX F237-P240) of this sheet arises from the cleavage and removal of the prodomain and the subsequent relocation of the N-terminus to enable association with the enzyme domain20. Subsequently, a mobile loop is formed in the processed N-terminal (PfPMX F237-L252) region and anchored to the mature enzyme structure by incorporation into the b-sheet (Fig. 3B). This loop forms the edge of a sub-pocket within the S3 substrate binding site and its importance in inhibitor binding is discussed below. A single hairpin loop is centrally located on the outside of the substrate binding cleft (Fig. 3. A and B). The loop between residue Asn345-Asp352 had poor electron density and could not be structurally determined in PfPMX. These missing residues are located at the edge of the active site cleft and thus presumably not involved in ligand binding.
Aligning the apo PfPMX enzyme structure with that of another member of the plasmepsin family, plasmepsin V (PMV) in complex with a peptidomimetic inhibitor WEHI-842 (not shown in schematic for simplicity), shows that the PfPMX loop (residues Asn345-Asp352) has a closed conformation without requiring the engagement of a substrate or inhibitor (Fig. 3C)19. PfPMX consists of the core aspartic protease structure and lacks other domains present in PvPMV such as the two b-barrels present at the bottom of the structure and the ‘nepenthesin 1-type’ aspartyl protease (NAP1) fold (Fig. 3C). These sequences in PvPMV are likely involved in protein-protein interactions and access to the protease active site and the lack of these shows that PfPMX does not require additional domains to perform the basic function of proteolysis for its target protein substrates.
A modeled structure for PfPMIX was generated using the PfPMX structure and comparison has revealed that the key structural and functional residues in the active site are located in similar positions in the PfPMIX model (Fig. 3. D). PfPMIX has a 59 residue insert (I431-N490) that is not shown and as this feature and structure is unique to this protease it could not be accurately modeled (Fig. 3D, S2). This insert occurs within four residues on the N-terminal side of the active site amino acid residue D457 and its influence on substrate binding has not been determined to date. Although the modeled structure for PfPMIX shows similarity to that found for PfPMX, its electrostatic surface was predicted to have a charge reversal around the location of its S3 pocket, which could generate subtle changes in the substrate specificities between each of these enzymes (Fig. S5).
PMX/inhibitor structure and interactions that mediate inhibitor binding affinity and specificity. Structures were obtained for PfPMX in complex with WM382 (resolution 2.76 Å) as well as PvPMX in complex with WM382 (resolution 2.22 Å) and WM4 (resolution 3.35 Å) (Fig. 4 and Table S2). The structure of PvPMX had similarity to that obtained for PfPMX including the basic architecture of the active sites and binding of WM382, although there are specific regions in the catalytic cleft that show localised structural movements due to drug binding (discussed below) (Fig. 4). Both WM382 and WM4 inhibitors align with the active site residues and are positioned between the inner and outer (S2 flap) surfaces of the substrate binding pocket (Fig. 4A, D and G). The structures for the protease-inhibitor complexes for PfPMX/WM382, PvPMX/WM382 and PvPMX/WM4 showed that the models for the inhibitors matched the observed electron density found within the substrate binding pocket as shown in the OMIT diagrams (2Fo-Fc density contoured at 1.0 σ) (Fig. 4B, E and H).
WM4 and WM382 share a common template but they have different moieties projecting from them designed to promote enhanced interactions within the substrate binding pocket. These subtle structural variations have led to the observed differences in binding affinity and substrate specificity for each of these compounds with PfPMX and PvPMX (Fig. 4C, F, I) and subsequently PfPMIX. Hydrogen bonds are the strongest surface interactions occurring between the active site of the corresponding protease and the inhibitors within the structures of these complexes. Within the PvPMX-WM4 complex (Fig. 4I), hydrogen bonding occurs in the S1 pocket between the hydrogen atoms of an amine and imine group from the ‘warhead’ on WM4 and the active site aspartic acid residues in PvPMX (D231 and D421) (Fig. 4I). An additional hydrogen bond also occurs between the main chain carbonyl group of G423 and the amide hydrogen of the carbonyl amide moiety on WM4. Hence, hydrogen bonds tether WM4 to the wall of the S1 pocket at the back of the substrate binding cleft.
The hydrogen bonding pattern observed between WM382 with PfPMX and PvPMX was identical in both structures (Fig. 4C and F). The pattern contains the same hydrogen bonds observed for the PvPMX/WM4 structure (Fig. 4I) but has an additional bond occurring between the carbonyl of the carbonyl amide moiety of WM382 and the hydroxy hydrogen of a serine located in the S2 flap at the front of the substrate binding cleft (PfPMX S313 and PvPMX S278). This additional hydrogen bond enables tethering of WM382 to the front S2 pocket in addition to the back surface of the S1 pocket in the substrate binding cleft in PfPMX and PvPMX (Fig. 4C and F). This same hydrogen bond does not seem to form with WM4 as the positioning of the phenyl moiety in the S’1 and S’2 pockets is such that it results in a more downward placement of the central aromatic ring, shared in both compound structures, than observed in WM382. This slight change in relative placement (1.7 Å) has a flow on effect, with the carbonyl of the adjacent carbonyl amide moiety now being too far away from S278 to enable the formation of a hydrogen bond similar to one observed in WM382. Interestingly, the modeled structure for PfPMIX in complex with WM382 has a Ser to Thr amino acid substitution in the same position in the flap of the S2 pocket suggesting this additional hydrogen bond can occur in the PfPMIX/WM382 complex (Fig. S6).
Amino acid residues positioned within 4 Å of WM4 and WM382 in the PvPMX/inhibitor structures were visualized by mapping onto a surface representation of the structures tabled with their location in the substrate binding cleft and color-coded as common to both inhibitors and unique to a specific inhibitor (Fig. 5). The common interactions (orange) occur about the active site aspartic acid residues and the compound warhead in the S1 and S2 pockets (Fig. 5). The parent WM4 inhibitor (cyan) has specific interactions (green) which occur predominantly in the S1’/S2’ pockets via a unique phenyl group protruding into this area (Fig. 5B and D). The binding affinity (KD), as determined by SPR, for binding of WM4 to the PvPMX active site was 0.48 nM (Fig. 2D). Interestingly, the WM382-specific interactions (magenta) are located towards the opposite end of the substrate binding cleft, in the S2, S3 and S3 sub pocket areas (Fig. 5A and C). This inhibitor has a methylated chromane moiety that enables greater extension and interaction with residues in this region compared to the a-methyl benzyl moiety located in the same position in WM4. Furthermore, WM382 was positioned such that an additional hydrogen bond occurred between Ser278 (S2 pocket) and the carbonyl of the carbonyl amide moiety, which engages the flap and tethers WM382 between the front and back surfaces of the catalytic cleft and explains the stronger binding affinity of WM382 compared to WM4. This was reflected in the KD values determined by SPR for binding of WM382 to PvPMX and PfPMX (KD <0.1 nM).
Although WM4 and WM382 are both capable of inhibiting PfPMX function in P. falciparum only WM382 shows a dual specificity that includes potent inhibition of PfPMIX3. Based on the results above, these differences in specificity are due to differences in the structures for the substrate binding cleft for PfPMIX and PfPMX or PvPMX. Given that the KD for WM4 interacting with PfPMIX was 77 nM, 160-fold weaker than that for PfPMX (0.39 nM) and PvPMX (0.48 nM), this indicated that WM4 has decreased interaction with the surface in the S1’/S2’ pockets of PMIX and is the basis of the unique PMX specificity of this inhibitor compound. Interestingly, a large 59 amino acid loop, with unknown structure, is inserted between the two sub domains of the mature PfPMIX enzyme (Fig. S3). This loop attaches, at the C-terminal end, within six residues of the active site D495 and may destabilize or be responsible for a change in surface topography in the S1’/S2’area.
The binding affinity of WM382 for PfPMIX was the same as that obtained for PvPMX and PfPMX (ie. KD <0.1 nM). In the PMX structures, WM382 interacts with the S1-S3 pockets and was tethered via four hydrogen bonds to the front and back of the substrate binding cleft. In a modeled structure for PfPMIX (based on the structure of PvPMX/WM382) the same hydrogen bonding pattern can be predicted with a T293 replacement for the PvPMX S278/PfPMX S313 in the flap at the front of the substrate binding pocket. The model predicts a similar distribution of weaker dispersion forces about the S1 to S3 pockets. Collectively this supports a similarity in this region of the substrate binding surface in PMX and PMIX and the basis for the dual specificity observed for WM382 inhibition of these two proteases.
The localized structural response of plasmepsin X to enable inhibitor binding. For the PfPMX and PvPMX structure the S2 flap and the loop of the S3SP showed significant changes in conformation for inhibitor binding (Fig. 6). In the PfPMX apo structure the S2 flap, particularly between residues F311 to G314, was found to be twisted almost perpendicular to the substrate binding cleft resulting in F311 being orientated into and S313 (not shown) orientated away from the empty cleft. Meanwhile the S3SP loop (H242 to F248) has a width from the Q247Ca to the L243Ca of 6.6 Å and residues within this loop have an outward projection (Fig. 6A). Entry of the inhibitor WM382 into the substrate binding cleft of PMX appears to have occurred from the S’ side of the cleft because of the unilateral change in orientation in the most affected residues. As a result, the amino acid F311 has moved 4.2 Å from where it was positioned in the apo structure and instead of projecting inward toward the cavity space of the cleft, the side chain has been reorientated toward the S2 flap to provide sufficient spatial separation from inhibitor WM382. Amino acid residue S313 was also repositioned via approximately a 90˚ rotation and a 4.8 Å directional shift in the hydroxy group of this residue. This structural change subsequently enables a hydrogen bond to occur between inhibitor WM382 and the hydroxy moiety of S313 as discussed previously (Fig. 4C).
The positioning of the WM382 warhead for interaction with the active site aspartic acid residues of PfPMX also requires the S3SP loop to be displaced further out of the cleft as shown by the 3 Å shift to the right and the width of the loop (Q247Ca to L243Ca) was compressed by 1.2 Å (Fig. 6A). Otherwise, the methylated chroman moiety of WM382 would collide with residues forming the S3SP loop. Furthermore, the outward projecting residues of the S3SP loop observed in the PfPMX apo structure are found to be orientated more upward and toward the inside of the loop in the PfPMX/WM382 structure. This reorientation of the S3SP residues enables the loop to be stabilized by an increased number of hydrogen bonds (Fig. 6 and Table S3).
As discussed previously, the S3SP loop is believed to be obtained from the rearrangement of the unstructured residual pro-sequence remaining after the autolytic cleavage events required to activate PMX, via a similar process described for other aspartyl proteases (autolytic activation)20. In the PfPMX apo structure the S3SP loop was quite mobile and has limited rigidity due to the low number of observed hydrogen bonds between residues within the loop (Fig. 6D and Table S3). In comparison, the structure obtained for PfPMX/WM382 complex has eight hydrogen bonds within the loop structure. This has arisen due to inhibitor induced compression of the loop and the inward reorientation of loop residues (Fig. 6E). The hydrogen bond pattern is three dimensional and not only increases the rigidity within the loop but also tethers the loop to a region outside via a hydrogen bond between Q247 and D245 (Fig. 6E and Table S3).
The S3SP loop structure for the PvPMX/WM382 complex has the same number of hydrogen bonds as the S3SP loop in PfPMX/WM382 complex but the hydrogen pattern was slightly different due to the influence of D323 (PvPMX) rather than S359 (PfPMX) as the external tethering point for the S3SP loop (Fig. 6F and Table S3). The loop structure in the PvPMX/WM4 complex has six hydrogen bonds and incorporates both internal and external hydrogen bond tethering points for increased loop rigidity. The a-methyl benzyl moiety of WM4 does not protrude as far into the S3SP as the methylated chromane moiety of WM382 and likely influences positioning of the D210 residue in the structure of the PvPMX/WM4, as two hydrogen bonds involving Q212 and D210 are not observed. Hence, the S3SP loop becomes stabilized by inhibitor displacement and loop compression with reorientation of loop residues that favor hydrogen bond formation leading to increased loop stability. This region was not obvious in the structure of the apo form of PfPMX. The S3SP is consequently, an important region for increasing affinity of binding for members of this inhibitor family to PMIX and PMX via hydrogen bond formation and increased Van der Waals interactions.